[{"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-001", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed123.jsonl", "pred": "A", "model_outputs": "Here is a step-by-step analysis of the clinical vignette:\n\n1.  Analyze the Patient's Presentation: The patient is a 45-year-old woman presenting with acute pancreatitis (evidenced by elevated lipase and CT findings) and a history of recurrent kidney stones.\n2.  Evaluate the Laboratory Data:\n    *   Calcium: 11.8 mg/dL (Hypercalcemia).\n    *   PTH: 85 pg/mL (Elevated).\n    *   Lipase: 1200 U/L (Consistent with pancreatitis).\n3.  Interpret the Physiology: In a normal physiological state, hypercalcemia should suppress the release of Parathyroid Hormone (PTH). The combination of hypercalcemia and an elevated (or inappropriately normal) PTH level is the diagnostic hallmark of Primary Hyperparathyroidism.\n4.  Connect the Findings:\n    *   Kidney Stones: Recurrent calcium oxalate stones are a classic complication of the hypercalciuria associated with primary hyperparathyroidism.\n    *   Pancreatitis: Hypercalcemia is a known metabolic cause of acute pancreatitis (often remembered in the mnemonic \"stones, bones, groans, and psychiatric overtones,\" where \"groans\" can refer to pancreatitis or constipation). High calcium levels can lead to the activation of trypsinogen within the pancreas and the formation of pancreatic duct stones.\n5.  Assess the Options:\n    *   A. Primary hyperparathyroidism due to parathyroid adenoma: This option explains all the findings: the high calcium, high PTH, kidney stones, and the resultant pancreatitis caused by hypercalcemia. This is the most direct and likely etiology.\n    *   B. Autoimmune pancreatitis: This typically presents with elevated IgG4 and characteristic imaging (sausage-shaped pancreas) but does not explain the hypercalcemia or elevated PTH.\n    *   C. Hereditary pancreatitis: Usually presents at a younger age and does not cause hypercalcemia/elevated PTH.\n    *   D. Hypertriglyceridemia: While a cause of pancreatitis, it does not explain the calcium and PTH abnormalities.\n    *   E. Gastrinoma: While Multiple Endocrine Neoplasia type 1 (MEN1) involves parathyroid and pancreatic tumors, the direct cause of the pancreatitis described here is the hypercalcemia resulting from the parathyroid issue. There is no evidence of peptic ulcer disease to suggest a gastrinoma, and a gastrinoma itself (acid hypersecretion) is not the cause of the pancreatitis.\n\nConclusion: The patient has biochemical evidence of primary hyperparathyroidism. Hypercalcemia is a rare but established cause of acute pancreatitis.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-002", "question": "A 52-year-old man with alcohol-related cirrhosis presents with acute upper GI bleeding. During emergent endoscopy, active spurting is seen from a large duodenal ulcer in the posterior bulb. After epinephrine injection and placement of two through-the-scope clips, bleeding continues. The following day, he develops fever and severe abdominal pain. CT shows retroperitoneal air and fluid tracking along the right psoas muscle. What is the most appropriate management?", "options": ["Angiographic embolization of the gastroduodenal artery", "Emergency laparotomy with duodenal diversion", "Percutaneous drainage of the retroperitoneal collection", "Repeat endoscopy with over-the-scope clip placement", "IV antibiotics and serial abdominal exams"], "answer": "B", "answer_index": 1, "explanation": "This scenario describes a posterior duodenal ulcer perforation into the retroperitoneum following endoscopic intervention. Given the ongoing bleeding and established contamination, definitive surgical management with duodenal diversion (e.g., Graham patch closure with gastrodujunostomy) is required. Angioembolization would address bleeding but not the perforation. Percutaneous drainage cannot control the duodenal leak. Repeat endoscopy is contraindicated with known perforation. Antibiotics alone would lead to uncontrolled sepsis.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-016", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "A", "model_outputs": "This patient presents with a complex scenario of a posterior duodenal bulb ulcer with two major complications: failed endoscopic hemostasis (\"bleeding continues\" after clipping) and an iatrogenic or progression-related retroperitoneal perforation (indicated by fever, severe abdominal pain, and retroperitoneal air/fluid on CT).\n\nThe management decision must balance the need for source control (stopping the bleeding and managing the perforation) with the patient's comorbidities. The patient has alcohol-related cirrhosis, which places him at very high risk for perioperative mortality if emergency laparotomy (Option B) were performed. Surgical management of a posterior duodenal perforation often requires difficult maneuvers like duodenal diversion or pyloric exclusion, carrying prohibitive risks in decompensated liver disease.\n\nOption E (IV antibiotics and serial exams) would be the standard conservative management for a contained retroperitoneal perforation if the patient were stable and not bleeding. However, the history of failed hemostasis (\"bleeding continues\") implies the gastroduodenal artery (GDA) is not secure, and leaving a high-risk bleeding vessel untreated is dangerous.\n\nOption D (Repeat endoscopy with OTSC) is an effective rescue therapy for acute bleeding and immediate perforation. However, in the setting of a \"delayed\" diagnosis (the following day) with established retroperitoneal contamination (fluid tracking), repeat insufflation carries the risk of worsening the dissection or causing tension pneumoperitoneum/pneumothorax. Furthermore, visualizing and closing a perforation in a field of edema, clots, and clips from the previous day can be technically very difficult and unreliable.\n\nOption C (Percutaneous drainage) addresses the septic collection but does not address the unsecured GDA.\n\nOption A (Angiographic embolization of the gastroduodenal artery) is the most appropriate management for the bleeding component in a high-risk surgical candidate. Angiography can definitively secure the bleeding vessel (salvage for failed endoscopy) without the trauma of general anesthesia and laparotomy. Once the hemorrhage risk is controlled via embolization, the retroperitoneal perforation can often be managed conservatively with antibiotics (and percutaneous drainage if a discrete abscess forms). This \"minimally invasive\" strategy offers the best chance of survival for a cirrhotic patient with this \"double hit\" complication.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-003", "question": "A 48-year-old woman with a history of systemic lupus erythematosus (SLE) on hydroxychloroquine and low-dose prednisone presents with 3 weeks of progressive dyspnea on exertion and dry cough. High-resolution CT shows diffuse ground-glass opacities with superimposed fine reticulation and subpleural sparing. Bronchoalveolar lavage reveals lymphocytic predominance (65%) with CD4:CD8 ratio of 0.8. Pulmonary function tests show a restrictive pattern with severely reduced DLCO (38% predicted). Which of the following is the most appropriate next step in management?", "options": ["Initiate high-dose intravenous methylprednisolone followed by oral prednisone 1 mg/kg/day", "Add mycophenolate mofetil to current immunosuppression", "Discontinue hydroxychloroquine and observe for 4 weeks", "Perform surgical lung biopsy to confirm usual interstitial pneumonia pattern", "Start rituximab therapy without additional testing"], "answer": "B", "answer_index": 1, "explanation": "The presentation is classic for lymphocytic interstitial pneumonia (LIP) associated with SLE, characterized by ground-glass opacities with reticulation, lymphocytic BAL, and low CD4:CD8 ratio. LIP in connective tissue disease typically requires more aggressive immunosuppression beyond steroids alone. Mycophenolate mofetil is the preferred steroid-sparing agent for SLE-associated interstitial lung disease with this pattern. High-dose steroids alone (A) are insufficient for progressive LIP. Hydroxychloroquine cessation (C) is unlikely to reverse established ILD. Surgical biopsy (D) is unnecessary with characteristic HRCT and BAL findings. Rituximab (E) is reserved for refractory cases after conventional immunosuppression fails.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed124-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed124.jsonl", "pred": "A", "model_outputs": "This patient presents with signs and symptoms consistent with Systemic Lupus Erythematosus (SLE)-associated Interstitial Lung Disease (ILD), specifically the Nonspecific Interstitial Pneumonia (NSIP) pattern.\n\n1.  Diagnosis:\n    *   HRCT: The description of \"diffuse ground-glass opacities with superimposed fine reticulation and subpleural sparing\" is the classic radiographic appearance of NSIP. Subpleural sparing is a key distinguishing feature from Usual Interstitial Pneumonia (UIP).\n    *   BAL: A lymphocytic predominance (65%) supports a cellular, inflammatory process (Cellular NSIP). A CD4:CD8 ratio < 1 is commonly seen in autoimmune-related ILD or drug-induced subtypes, though less specific.\n    *   Clinical: New onset/progressive dyspnea in a lupus patient. The exclusion of infection would be standard (and BAL lymphocytosis points away from bacterial/PCP etiologies which would typically show neutrophils or organisms, though PCP can have lymphocytes, the NSIP CT pattern makes SLE-ILD the primary diagnosis).\n\n2.  Management:\n    *   The patient has Cellular NSIP, indicated by the ground-glass opacities (active inflammation/alveolitis) and BAL lymphocytosis. Cellular NSIP generally responds very well to corticosteroid therapy.\n    *   The patient has severe impairment (DLCO 38%).\n    *   Option A: For active, symptomatic, and severe SLE-ILD (or acute lupus pneumonitis), the standard first-line treatment is high-dose systemic corticosteroids. Given the severity, pulse intravenous methylprednisolone followed by high-dose oral prednisone is the most appropriate initial step to rapidly control inflammation and prevent respiratory failure.\n    *   Option B: Mycophenolate mofetil (MMF) is an effective therapy for SLE-ILD and is often used as a steroid-sparing agent or for maintenance. However, in the setting of acute/subacute progression with severe impairment, initiating MMF alone (or adding it to *low-dose* prednisone) is insufficient because it has a slower onset of action compared to high-dose corticosteroids. It is often started concurrently or after induction with steroids, but the *immediate* priority is the steroid pulse.\n    *   Option C: Hydroxychloroquine-induced lung disease is rare compared to SLE-ILD. Discontinuing the drug and \"observing\" a patient with severe respiratory compromise (DLCO 38%) is unsafe.\n    *   Option D: A surgical lung biopsy is invasive and carries high risk in a patient with this degree of impairment. The diagnosis of CTD-ILD is highly probable given the history of SLE and the characteristic HRCT/BAL findings; thus, biopsy is not required for management.\n    *   Option E: Rituximab is generally reserved for refractory cases.\n\nTherefore, aggressive corticosteroid therapy is the indicated next step.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-004", "question": "A 35-year-old woman with tuberous sclerosis complex develops rapidly progressive renal insufficiency. Imaging shows massively enlarged kidneys with innumerable angiomyolipomas, the largest measuring 8 cm. What is the most appropriate intervention to preserve renal function?", "options": ["Selective arterial embolization of the dominant tumors", "Initiation of everolimus therapy", "Bilateral nephrectomy with dialysis initiation", "Cryoablation of the largest angiomyolipomas", "Radical nephrectomy of the more affected kidney"], "answer": "B", "answer_index": 1, "explanation": "In TSC with diffuse angiomyolipomatosis causing renal failure, everolimus (an mTOR inhibitor) is first-line therapy as it targets the underlying pathophysiology, can reduce tumor size by over 50%, and preserves renal function better than procedural interventions. Embolization or ablation would be impractical for innumerable tumors and could accelerate renal decline. Nephrectomy should be avoided unless absolutely necessary for hemorrhage control. Everolimus addresses the systemic nature of TSC renal involvement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-017", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "B", "model_outputs": "This question describes a patient with Tuberous Sclerosis Complex (TSC) presenting with massively enlarged kidneys and innumerable angiomyolipomas (AMLs), resulting in renal insufficiency. The goal is to determine the best intervention to preserve renal function.\n\n1.  Pathophysiology: In TSC, mutations in the *TSC1* or *TSC2* genes lead to constitutive activation of the mTOR (mechanistic target of rapamycin) pathway, resulting in cell proliferation and tumors like angiomyolipomas. These tumors can grow very large, replacing normal renal parenchyma and compressing functional tissue, leading to renal failure.\n2.  Evaluate Options:\n    *   Nephrectomy (Options C and E): Radical or bilateral nephrectomy would result in the immediate loss of renal function, necessitating dialysis or transplantation. This contradicts the goal of preserving function. In TSC, nephron-sparing approaches are critical because the disease is bilateral and progressive.\n    *   Cryoablation (Option D): Ablation is typically reserved for small, solitary lesions (usually <4 cm). It is not feasible for \"innumerable\" tumors or massive lesions (8 cm), as it would not effectively treat the global disease burden.\n    *   Selective Arterial Embolization (Option A): This is the first-line treatment for acute hemorrhage from an AML. While it reduces tumor size, it typically targets specific dominant vessels. It carries risks of \"post-embolization syndrome\" and, crucially, inadvertent infarction of healthy renal tissue, which could worsen the already compromised renal function.\n    *   mTOR Inhibitors / Everolimus (Option B): Clinical trials (e.g., EXIST-2) and international consensus guidelines recommend mTOR inhibitors (like everolimus or sirolimus) as the first-line therapy for asymptomatic, growing angiomyolipomas >3 cm. These drugs target the underlying molecular defect, leading to a significant reduction in tumor volume (often 50% or more) and halt progression. High-quality evidence shows that mTOR inhibitors can stabilize and often improve renal function in TSC patients with extensive AML burden by shrinking the tumors and relieving compression on the renal parenchyma, thus sparing nephrons.\n\nConclusion: For a patient with massive, diffuse AML burden causing renal insufficiency (without active hemorrhage), systemic therapy with an mTOR inhibitor is the most appropriate intervention to shrink tumor volume and preserve remaining renal function.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "source_question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251219T221819110Z_deepseek-v3.2_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T221819110Z_deepseek-v3.2_seed133.jsonl", "pred": "A", "model_outputs": "The patient is a 62-year-old man with essential thrombocythemia (ET), a myeloproliferative neoplasm (MPN) characterized by a hypercoagulable state. He presents with a major stroke (MCA infarction). The key findings to integrate are:\n1.  Hypercoagulable State: The patient has a JAK2 V617F-positive MPN. Although his platelet count is controlled on hydroxyurea, the mutation itself confers a prothrombotic state due to activated leukocytes and platelets.\n2.  Multiple Brain Lesions: The MRI shows \"multiple small enhancing lesions in both cerebral hemispheres\" in addition to the large MCA infarct. Bilateral lesions typically indicate a cardioembolic source or a systemic process affecting the vasculature, rather than a single local thrombotic event.\n3.  Enhancing Lesions: In the context of stroke, contrast enhancement usually appears in the subacute phase (3 days to weeks) due to blood-brain barrier breakdown. The presence of multiple enhancing lesions suggests a \"shower\" of emboli that may have occurred over time (some subacute, one acute major one).\n4.  Negative Infectious Workup: Negative blood cultures and lack of fever make infective endocarditis (septic emboli) less likely.\n5.  Negative TTE: Transthoracic echocardiography (TTE) is often negative for small vegetations. Transesophageal echocardiography (TEE) is more sensitive.\n\nAnalysis of Options:\n*   A. Nonbacterial thrombotic endocarditis (NBTE): Also known as marantic endocarditis, this condition is characterized by sterile vegetations composed of fibrin and platelets on cardiac valves. It is strongly associated with hypercoagulable states, including malignancies and MPNs (like ET), and systemic lupus erythematosus (Libman-Sacks). These vegetations are friable and easily embolize, leading to multiple strokes in different vascular territories (bilateral). The lesions are often small and can be multiple. TTE frequently misses these small vegetations. The \"enhancing\" nature is consistent with subacute embolic infarcts. This fits all the clinical data.\n*   B. Leukoencephalopathy from hydroxyurea toxicity: Hydroxyurea CNS toxicity is rare and typically presents with diffuse symptoms or white matter changes, not focal infarcts or discrete enhancing nodules mimicking emboli.\n*   C. Transformation to acute myeloid leukemia (AML): CNS involvement (myeloid sarcoma/chloroma) can occur, but usually in the setting of uncontrolled blast counts in the blood (blast crisis). The patient's platelet count is controlled, and there is no mention of blasts or pancytopenia.\n*   D. Cerebral vasculitis secondary to JAK2 mutation: While JAK2 mutations create a pro-inflammatory and pro-thrombotic environment, \"cerebral vasculitis\" (inflammation of the vessel wall) is not the primary mechanism of stroke in ET. The mechanism is thrombosis.\n*   E. Paradoxical embolism through patent foramen ovale: This requires a venous source (DVT) and a right-to-left shunt. While possible, NBTE is a direct complication of the patient's underlying hypercoagulable disease affecting the arterial side (valves) and explains the findings better without assuming a DVT/PFO complex.\n\nTherefore, the patient likely has nonbacterial thrombotic endocarditis resulting from his underlying MPN, leading to embolic strokes.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-006", "question": "A 28-year-old woman develops recurrent sinopulmonary infections and bronchiectasis. Workup reveals absent IgA, markedly reduced IgG and IgM, and absent B cells on flow cytometry. Genetic testing identifies a mutation in the λ5 surrogate light chain gene. Which specific immunological abnormality explains her infection pattern?", "options": ["Failure of heavy chain rearrangement in pre-B cells", "Defective VDJ recombination due to RAG deficiency", "Absence of the pre-B cell receptor complex signaling", "Mutation in the BLNK adapter protein preventing PLCγ activation", "Loss of BTK enzyme function disrupting B cell maturation"], "answer": "C", "answer_index": 2, "explanation": "The λ5 gene encodes part of the surrogate light chain critical for pre-B cell receptor formation. Without functional pre-BCR signaling, B cells fail to proliferate and mature at the pre-B cell stage, causing the arrested development seen here. This is distinct from Bruton's tyrosine kinase deficiency (which affects later signaling) or RAG deficiencies (which impair initial recombination). The specific λ5 mutation explains the profound B cell deficiency and hypogammaglobulinemia.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "C", "model_outputs": "The clinical presentation of recurrent infections, bronchiectasis, absent B cells, and pan-hypogammaglobulinemia in a female patient suggests an autosomal recessive form of agammaglobulinemia. The question specifies a mutation in the $\\lambda$5 (lambda-5) surrogate light chain gene (*IGLL1*).\n\n1.  B Cell Development: during the maturation of B cells in the bone marrow, Pro-B cells undergo immunoglobulin heavy chain gene rearrangement (VDJ recombination).\n2.  Pre-BCR Formation: If a productive heavy chain ($\\mu$ chain) is produced, it must pair with the surrogate light chain (SLC) to form the pre-B cell receptor (pre-BCR). The SLC is composed of two proteins: VpreB and $\\lambda$5.\n3.  Checkpoint: The assembly and expression of the pre-BCR on the cell surface serve as a critical checkpoint. Spontaneous signaling through the pre-BCR complex allows the cell to survive, proliferate, shut down further heavy chain rearrangement (allelic exclusion), and proceed to light chain rearrangement.\n4.  Pathophysiology: A mutation in $\\lambda$5 prevents the formation of a functional surrogate light chain. Consequently, the $\\mu$ heavy chain cannot pair to form the pre-BCR complex. Without the pre-BCR, the developing B cell does not receive the necessary signaling to survive and advance to the next stage of development. This results in an arrest of B cell differentiation at the pro-B to pre-B transition, leading to a total lack of mature B cells and antibodies (agammaglobulinemia).\n\n*   Option A is incorrect because heavy chain rearrangement occurs via RAG enzymes; the defect here is the inability to *sense* the successful rearrangement, not the rearrangement itself.\n*   Option B describes RAG deficiency, which affects the recombination process directly.\n*   Option D describes a defect in BLNK, a scaffold protein downstream of the BCR/pre-BCR, which is a different genetic cause.\n*   Option E describes X-linked Agammaglobulinemia (Bruton's), caused by BTK mutations.\n\nTherefore, the specific abnormality caused by the $\\lambda$5 mutation is the failure to form the pre-BCR and the subsequent lack of signaling required for development.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-007", "question": "A 44-year-old woman presents with 8 months of progressive proximal muscle weakness, heliotrope rash, and Gottron's papules. Muscle biopsy shows perfascicular atrophy and MAC deposition on capillaries. She tests positive for anti-MDA5 antibodies. Which of the following complications carries the highest immediate mortality risk?", "options": ["Aspiration pneumonia", "Cardiac conduction abnormalities", "Rapidly progressive interstitial lung disease", "Malignancy-associated deterioration", "Calcinosis universalis"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 antibody-positive dermatomyositis is strongly associated with rapidly progressive interstitial lung disease (RP-ILD), which has mortality exceeding 50% within 6 months despite treatment. This subtype shows characteristic skin findings but often minimal muscle involvement, with MAC deposition on capillaries. While aspiration (A) and cardiac issues (B) occur in myositis, RP-ILD is the most lethal complication in anti-MDA5 patients. Malignancy risk (D) is lower with anti-MDA5 than with anti-TIF1γ. Calcinosis (E) is chronic but not immediately life-threatening. Early recognition and aggressive immunosuppression for RP-ILD are critical in anti-MDA5 dermatomyositis.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "source_question_id": "20251205T082731900Z_deepseek-v3.2_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251205T082731900Z_deepseek-v3.2_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251205T082731900Z_deepseek-v3.2_seed124.jsonl", "pred": "C", "model_outputs": "Here is the step-by-step analysis to determine the correct answer:\n\n1.  Diagnosis: The patient presents with classic signs of Dermatomyositis (DM), including proximal muscle weakness, heliotrope rash, and Gottron's papules. The muscle biopsy findings of perifascicular atrophy and MAC deposition on capillaries are pathognomonic for DM.\n\n2.  Serological Marker: The patient tests positive for anti-MDA5 antibodies (anti-Melanoma Differentiation-Associated protein 5).\n\n3.  Clinical Associations with anti-MDA5:\n    *   This antibody is distinctively associated with a phenotype often referred to as clinically amyopathic dermatomyositis (CADM), although patients can present with varying degrees of muscle involvement (as seen in this patient).\n    *   One of the most characteristic cutaneous findings is palmar papules and skin ulceration.\n    *   However, the most clinical significant and dangerous association is with Rapidly Progressive Interstitial Lung Disease (RP-ILD).\n\n4.  Mortality Risk Analysis:\n    *   Rapidly progressive interstitial lung disease (Option C): Patients with anti-MDA5 positive DM are at a very high risk for RP-ILD. This condition is often resistant to conventional therapy and carries a high mortality rate (reported up to 50-80% in various studies) due to acute respiratory failure. This is the leading cause of death in this specific subset of patients.\n    *   Malignancy (Option D): While Dermatomyositis in adults is generally associated with an increased risk of malignancy (specifically associated with anti-TIF1-gamma and anti-NXP2 antibodies), studies suggest that anti-MDA5 positive patients actually have a lower risk of malignancy compared to these other subtypes. The immediate mortality risk comes from the lungs, not cancer.\n    *   Aspiration pneumonia (Option A) and Cardiac conduction abnormalities (Option B) are potential complications of inflammatory myopathies due to muscle/cardiac involvement, but they do not represent the specific, high-frequency, high-mortality complication defined by the anti-MDA5 antibody profile.\n    *   Calcinosis (Option E) is a cause of morbidity, particularly in juvenile DM or with anti-NXP2 antibodies, but is rarely a cause of immediate mortality.\n\n5.  Conclusion: Given the presence of anti-MDA5 antibodies, the complication carrying the highest immediate mortality risk is rapidly progressive interstitial lung disease.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-008", "question": "A 30-year-old missionary presents with a slowly enlarging scalp lesion after returning from Bolivia. biopsy demonstrates lobulated granulomatous inflammation with rare 5-7 μm budding yeast. Culture on brain-heart infusion agar at 25°C shows cream-colored colonies that convert to yeast form at 37°C. What is the most appropriate antifungal therapy?", "options": ["Itraconazole for 6-12 months", "Amphotericin B lipid complex followed by itraconazole", "Voriconazole indefinitely", "Posaconazole with therapeutic drug monitoring", "Fluconazole for 3-6 months"], "answer": "A", "answer_index": 0, "explanation": "The presentation describes cutaneous granulomas caused by Paracoccidioides brasiliensis, endemic to Latin America. Itraconazole is first-line for non-severe disease, with 6-12 months treatment typically achieving cure. Amphotericin B is reserved for severe disseminated disease. Voriconazole has variable activity against Paracoccidioides. Fluconazole is less effective due to higher relapse rates. The dimorphic growth pattern and geographic history are classic for this infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed130-019", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed130.jsonl", "pred": "A", "model_outputs": "The clinical presentation and laboratory findings are consistent with a fungal infection caused by a thermally dimorphic fungus. The key features include:\n1.  Epidemiology: Travel to Bolivia (endemic region for several mycoses).\n2.  Clinical: Chronic, slowly enlarging scalp lesion (cutaneous/subcutaneous mycosis).\n3.  Pathology: Granulomatous inflammation with \"rare 5-7 μm budding yeast.\"\n    *   While *Histoplasma capsulatum* is typically 2-4 μm and intracellular, and *Blastomyces dermatitidis* is typically 8-15 μm with broad-based budding, the size 5-7 μm is intermediate. However, the presence of rare yeasts in a granulomatous background is often seen in cutaneous manifestations of these endemic mycoses (particularly *Blastomyces* or *Sporothrix*, or occasionally *Histoplasma*). The description of lobulated inflammation is often associated with the pseudoepitheliomatous hyperplasia seen in blastomycosis or sporotrichosis, or mimics of Lobomycosis (which is unculturable).\n4.  Microbiology: The organism grows as a mold (cream-colored colonies) at 25°C and converts to a yeast form at 37°C. This confirms a thermally dimorphic fungus (e.g., *Histoplasma*, *Blastomyces*, *Sporothrix*, *Paracoccidioides*). *Cryptococcus* is not thermally dimorphic in this pattern (yeast at both temps).\n\nTreatment Analysis:\nThe patient has a localized cutaneous lesion (\"slowly enlarging\") and there is no mention of severe systemic symptoms, sepsis, or CNS involvement.\n*   Mild-to-moderate endemic mycoses (Histoplasmosis, Blastomycosis, Paracoccidioidomycosis, and Lymphocutaneous Sporotrichosis) are treated with Itraconazole.\n*   Severe or life-threatening disease is treated with Amphotericin B induction followed by Itraconazole.\n*   Fluconazole (Option E) is generally second-line or less effective for Histoplasmosis and Blastomycosis compared to Itraconazole. It is the treatment of choice for Coccidioidomycosis (not suggested by morphology) or consolidation of Cryptococcus.\n*   Posaconazole (Option D) and Voriconazole (Option C) are usually reserved for salvage therapy or cases intolerant of Itraconazole.\n\nThe standard duration of therapy for mild-to-moderate histoplasmosis or blastomycosis is 6-12 months. This matches Option A. The presentation (scalp lesion, granulomatous, dimorph) is treatable with this regimen regardless of the exact species (Histo vs Blasto vs Sporo).\n\nThe correct answer represents the standard of care for a mild/localized infection with a dimorphic fungus.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-009", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed131.jsonl", "pred": "B", "model_outputs": "This patient has metastatic HER2-positive (IHC 3+) breast cancer and has experienced disease progression while on maintenance therapy following first-line treatment with a taxane, trastuzumab, and pertuzumab. This constitutes progression in the second-line setting (or progression on first-line leading to the need for second-line therapy).\n\nAccording to the NCCN Guidelines and the results of the DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd) is the preferred second-line systemic therapy for patients with HER2-positive metastatic breast cancer who have received prior trastuzumab and taxane. In the DESTINY-Breast03 trial, T-DXd demonstrated superior progression-free survival and overall survival compared to trastuzumab emtansine (T-DM1).\n\nLet's review the other options:\n*   A. Continue trastuzumab/pertuzumab and add capecitabine: While continuing anti-HER2 blockade and switching the chemotherapy backbone is a strategy, switching to an antibody-drug conjugate (like T-DXd) is the preferred standard of care due to superior efficacy.\n*   C. Switch to lapatinib plus capecitabine: This regimen is typically reserved for later lines of therapy (third-line or beyond) or specific situations involving CNS metastases (though tucatinib-based regimens are often preferred there). It is inferior to T-DXd in this setting.\n*   D. Switch to everolimus plus exemestane: This regimen is indicated for hormone receptor-positive (HR+), HER2-negative breast cancer. This patient is ER-/PR- (HR-negative).\n*   E. Switch to alpelisib plus fulvestrant: Alpelisib is indicated for HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. Although this patient has a PIK3CA mutation, her tumor is HR-negative and treated as HER2-positive. Therefore, endocrine-based therapy with alpelisib is not appropriate.\n\nRegarding the pathology results: ASCO/CAP guidelines define HER2 positivity as IHC 3+. While NGS did not detect amplification, IHC 3+ is the clinical standard for eligibility for anti-HER2 therapy. Additionally, T-DXd has efficacy in HER2-low disease, reinforcing its utility here, but the patient remains eligible for HER2-positive protocols based on the IHC.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_deepseek-v3.2_p03", "question_id": "ABMS20260101_deepseek-v3.2_p03-010", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy / Immunology", "source_quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "source_question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/deepseek-v3.2/20251216T183904770Z_deepseek-v3.2_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T183904770Z_deepseek-v3.2_seed131.jsonl", "pred": "A", "model_outputs": "The patient's clinical presentation (severe headache, photophobia, neck stiffness) and timing relative to IVIG infusion are suggestive of an IVIG-associated adverse neurological reaction. While classic drug-induced aseptic meningitis (DIAM) typically presents with cerebrospinal fluid (CSF) pleocytosis (elevated WBCs), this patient's CSF shows a normal cell count (2/μL) but elevated opening pressure (28 cm H2O). This constellation of findings is consistent with IVIG-associated intracranial hypertension or severe vascular headache/migraine syndrome, which can mimic meningitis symptoms (meningismus). These reactions are often driven by the high peak serum levels of IgG, increased serum viscosity, and fluid/osmotic shifts occurring during and immediately after the intravenous bolus administration.\n\nThe most effective strategy to prevent the recurrence of these systemic/neurological adverse events while maintaining immune protection is to switch to subcutaneous immunoglobulin (SCIG). SCIG therapy involves the slow absorption of IgG from the subcutaneous tissue into the systemic circulation, typically administered weekly. This method avoids the high peak serum IgG concentrations and rapid osmotic/viscosity shifts associated with IVIG, thereby significantly reducing or eliminating systemic side effects like severe headaches and aseptic meningitis phenomena.\n\nOption B (high-dose steroids) is a treatment for acute reactions or a premedication for infusion reactions, but long-term high-dose prophylactic steroid use is not ideal given the side effect profile and the availability of alternative administration routes.\nOption C (changing formulation) might help in some cases of product-specific intolerance, but SCIG is more definitively effective for peak-related neurological side effects.\nOption D (72-hour infusion) is logistically difficult for a monthly maintenance therapy and essentially attempts to mimic the pharmacokinetic profile that SCIG achieves more practically.\nOption E is not the standard of care for CVID.\n\nThe answer is (A)"}]